SecBot SecBot
6-K ·Filed Aug 19, 2026

CMMB

Chemomab Therapeutics Ltd.
NEUTRAL
Impact 6/10
Horizonweeks Processed2mo ago SEC0001178913-26-004193
Notable filing: 6-K
Actionable Insight • Neutral

The merger with Scipher is the dominant catalyst. Monitor for SEC review of the S-4, shareholder vote, and closing expected by year-end 2026. The standalone cash position is insufficient beyond Q1 2027, making deal completion critical. Post-merger, the key catalyst is the Phase 2 RA trial initiation in H1 2027 and data in H1 2028. The CVRs provide optionality on nebokitug milestones but are not tradeable.

DirectionNeutral
Confidencehigh
Horizonweeks

nebokitug

◆ Mixed Named in this 6-K
Impact
Phase
Phase 2 (complete); preparing Phase 3
Time to market
At least 4-6 years; Phase 3 PSC trial not yet initiated, and even if successful, filing and approval would follow several years later. The new RA program is even earlier-stage.
Next catalyst
None dated

What to watchThe just-announced merger with Scipher Medicine (all-stock, closing Q4 2026) reshapes the investment thesis: pre-merger Chemomab holders get ~32% of the combined entity plus CVRs tied to nebokitug milestones, while the new company will run an AI-guided Phase 2 RA trial. Watch for Phase 3 PSC trial financing clarity post-merger and the merger close vote. The stock already ran ~80% into the deal, much of the near-term re-rating may be priced in.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$2.09
T+0 close · Aug 19, 2026 · via day close
Latest settled
−33.01%
T+60 · $1.40
Vs SPY
−31.46%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 19 $2.09entry
  2. T+1 · 3mo ago −0.96%α −0.12% · $2.07
  3. T+5 · 3mo ago +23.92%α +24.31% · $2.59
  4. T+20 · 2mo ago +33.97%α +35.92% · $2.80
  5. T+60 · 5d ago −33.01%α −31.46% · $1.40
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Chemomab reported Q2 2026 financial results and provided a corporate update centered on the proposed all-stock merger with Scipher Medicine. The company had $6.7M in cash as of June 30, 2026, with a net loss of $2.2M for the quarter. The merger, which values the combined company at $150M pre-money, would give Chemomab shareholders ~32% ownership and CVRs tied to nebokitug milestones, with the combined entity trading under 'SCIP'. The filing also includes a going-concern warning, noting cash runway only through Q1 2027 absent the merger closing, and the company has no approved products or revenue.

Key Facts

  • Cash, cash equivalents and short-term bank deposits were $6.7M as of June 30, 2026, down from $8.0M as of March 31, 2026.
  • Net loss for Q2 2026 was $2.2M, compared to $2.1M in Q2 2025.
  • R&D expenses were $1.1M in Q2 2026 vs $1.3M in Q2 2025; G&A expenses were $1.1M vs $1.0M.
  • Chemomab entered a definitive merger agreement with Scipher Medicine on July 7, 2026, an all-stock transaction valuing the combined company at $150M pre-money.
  • Chemomab shareholders are expected to own ~32% of the combined company; Scipher holders ~68%, prior to a concurrent $30M PIPE.
  • Chemomab shareholders will receive CVRs: $10M upon FDA approval of nebokitug for any indication and $40M if the PSC program advances to Phase 3 or is partnered.
  • The combined company expects to trade on Nasdaq under ticker 'SCIP' and focus on a Phase 2 RA trial of nebokitug, with topline results expected H1 2028.
  • The company has incurred recurring losses of ~$116M, negative operating cash flow of $3.7M in H1 2026, and no approved products, raising substantial doubt about its ability to continue as a going concern.
  • Cash runway is expected to fund operations only through Q1 2027.
  • The company issued 34,760 ADSs under the LifeSci ATM during H1 2026 for net proceeds of ~$68K.

Financial Impact

Cash burn of $1.3M per quarter; cash runway through Q1 2027; merger provides $30M PIPE to extend runway through Phase 2 RA readout in H1 2028

cashnet lossdilution

Risk Factors

  • Merger may not close due to failure to obtain shareholder approval, SEC review issues, or tax rulings from the Israel Tax Authority.
  • The company has a going-concern warning and only ~6 months of cash runway without the merger closing.
  • Nebokitug is still in clinical development with no approved products and faces significant regulatory and clinical risk.
  • The combined company's stock will trade under a new ticker (SCIP), and current CMMB holders will own only ~32% of the combined entity.
  • The CVRs are non-transferable and contingent on future milestones that may never be achieved.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001178913-26-004193
Exhibit: exhibit_99-2.htm0001178913-26-004193
Exhibit: exhibit_99-3.htm0001178913-26-004193
Document: zk2635899.htm0001178913-26-004193
Document: 0001178913-26-004193-index-headers.html0001178913-26-004193
Document: 0001178913-26-004193-index.html0001178913-26-004193
Document: 0001178913-26-004193.txt0001178913-26-004193

Track record

15 reports on CMMB

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +33.01% at T+60 after the Aug 19, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13D Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
  2. Nov 10, 20266d ago DEFA14A Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
  3. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $1.18 Now $1.62 +37.29% settles Feb 1
  4. Nov 2, 202614d ago Press Release Neutral 5/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
  5. Oct 30, 202617d ago DEFM14A Neutral 6/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
  6. Oct 19, 202628d ago 6-K Neutral 3/10 Entry $1.18 Now $1.62 +37.29% settles Jan 15
  7. Sep 30, 20266w ago 6-K Neutral 4/10 Entry $1.30 Now $1.62 +24.62% settles Dec 28
  8. Aug 19, 202612w ago 6-K Neutral 6/10 Viewing Entry $2.09 to $1.40 Now $1.62 −22.49% ▼ −33.01% −31.46% vs SPY
  9. Aug 19, 202612w ago Press Release Bearish 6/10 Entry $2.09 to $1.40 Now $1.62 +22.49% ▲ +33.01% +31.46% vs SPY
  10. Jul 8, 202618w ago 6-K Bullish 7/10 Entry $1.97 to $1.19 Now $1.62 −17.77% ▼ −39.59% −41.91% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 9h 23m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 19, 2026